VIA
EGRX

Vident Investment Advisory’s Eagle Pharmaceuticals, Inc. EGRX Stock Holding History

Vident Investment Advisory’s Portfolio EGRX Stock Details EGRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-19,314
Closed -$778K – 826
2018
Q4 		$778K Sell
19,314
-2,710
-12% -$140K 0.04% 474
2018
Q3 		$1.53M Buy
+22,024
New +$1.67M 0.06% 383

Other funds holding EGRX

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PWAM
Park West Asset Management San Francisco, California $1.18B AUM 47.25% 1-Year Est. Return
HEC
Hudson Executive Capital New York $151M AUM 60.14% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JAM
JW Asset Management Miami Beach, Florida $244M AUM 71.51% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return

Vident Investment Advisory's EGRX Position: Q1 2019 in Review

Vident Investment Advisory sold out of Eagle Pharmaceuticals, Inc. (EGRX) in Q1 2019, closing a stake of 19,314 shares — an estimated $778K sold.

Vident Investment Advisory first reported a position in EGRX in Q3 2018 and held it in 2 quarters. The position peaked at $1.53M in Q3 2018. 182 funds tracked by Wall St. Rank hold EGRX as of Q1 2019.

  • Vident Investment Advisory reported no remaining Eagle Pharmaceuticals, Inc. position as of Q1 2019 after selling out during the quarter.
  • Vident Investment Advisory sold 19,314 Eagle Pharmaceuticals, Inc. shares in Q1 2019, an estimated $778K.
  • Vident Investment Advisory first reported a position in Eagle Pharmaceuticals, Inc. in Q3 2018 and held it in 2 quarters.
  • Vident Investment Advisory's Eagle Pharmaceuticals, Inc. position peaked at $1.53M in Q3 2018.
  • 182 funds tracked by Wall St. Rank held Eagle Pharmaceuticals, Inc. as of Q1 2019.

Based on Vident Investment Advisory's 13F filing for Q1 2019, filed 8 May 2019.